Serodus in-licenses Roche heart failure compound

Roche (SIX:ROG; OTCQX:RHHBY) granted Serodus A/S (Oslo, Norway) exclusive, worldwide rights to develop and commercialize RO1160367 (SER101). Next quarter, Serodus plans to start a Phase II trial of th...